Oculis Holding AG
corporate_fare Company Profile
Oculis Holding AG (NASDAQ:OCS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for OCS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-10, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for OCS spans 6-K, F-3ASR, 20-F.
Recent high-impact activity:
- Oculis Secures Full Worldwide Rights to Privosegtor, Eliminating Legacy Royalties
- Oculis Buys Out Privosegtor Rights from Accure for $3.8M Cash and 2M Shares, Ending Royalty Obligations
- Oculis Q2 Loss Narrows to CHF 10M, Cash Runway Extended to 2029
- FDA Greenlights Privosegtor Path for MS Relapses, IND Filing Set for Q4
- Shareholder Investigation Launched Against Oculis Over Alleged Misleading Statements on Failed Drug Trial
Financial Snapshot
Short Interest & Short Volume
9.91 days to coverFINRA reported short interest of 1,551,805 shares in OCS as of the September 15, 2026 settlement, a 4.1% increase from the prior period — about 9.9 days to cover at its recent average daily volume. On October 2, 2026, 51.7% of OCS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OCS, detected from its recent SEC filings · based on capital-structure filings through 2026-04-21.
Proposed Capital Authorization · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
OCS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.